NL
DE
Our spin-off Khondrion announced the dosing of first patient in their Khenergy study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children with a genetically confirmed primary mitochondrial disease and suffering from motor symptoms
Related news items
Meet Healthy Ideas, Healthy Returns
2 June 2023Do you have a golden idea to improve healthcare, but not the resources to realize it? Discover Healthy Ideas, Healthy Returns: a Benelux-wide public-private network offering opportunities for healthcare investments and propositions, among other things.
read moreAftermovie Investment Day 2022 and a new date for 2023!
13 December 2022Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.
read more
Successful matchmaking at Radboudumc Investment Day
7 October 2022On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.
read more
Radboudumc Investment Day 2022
26 September 2022Get ready for Radboudumc Investment Day 2022: October 5 in Nijmegen!
read more
Innovation by Predica Diagnostics BV improves cervical cancer screening
26 July 2022A joint financing round from ION+2 and the Thematic Technology Transfer Medtech Fund (TTT Medtech) allows the further development of molecular diagnostic tests for different cancers by Predica Diagnostics (Nijmegen, NL).
read more
